Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials

Journal of Human Nutrition and Dietetics

Volumn 31, Issue 1, 2018, Pages 67-84

  AbuMweis, S ^a   Jew, S ^b   Tayyem, R ^c   Agraib, L ^a  

^a HASHEMITE UNIVERSITY   (Jordan)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF JORDAN   (Jordan)

Author keywords

blood preesure; C recative protein; cardiovascular; docosahexaenoic acid; eicosapentaenoic acid; heart rate; inflammation; risk factors; triglyderides

Indexed keywords

C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIETARY SUPPLEMENT; DRUG EFFECT; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; TRIGLYCERIDES; YOUNG ADULT;

EID: 85021813294     PISSN: 09523871     EISSN: 1365277X     Source Type: Journal    
DOI: 10.1111/jhn.12493     Document Type: Article

References (190)

1. Gaziano TA (2007) Reducing the growing burden of cardiovascular disease in the developing world. Health Aff 26, 13–24.
2. Albert CM, Hennekens CH, O'Donnell CJ et al. (1998) Fish consumption and risk of sudden cardiac death. JAMA 279, 23–28.
3. Hu FB, Bronner L, Willett WC et al. (2002) Fish and omega-3 fatty acid intake and risk of coronaryheart disease in women. JAMA 287, 1815–1821.
4. Mozaffarian D, Bryson CL, Lemaitre RN et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 2015–2021.
5. Mozaffarian D, Longstreth WT Jr, Lemaitre RN et al. (2005) Fish consumption and stroke risk in elderly individuals: The Cardiovascular Health Study. Arch Intern Med 165, 200–206.
6. Larsson SC, Virtamo J & Wolk A (2011) Fish consumption and risk of stroke in Swedish women. Am J Clin Nutr 93, 487–493.
7. Wang C, Harris WS, Chung M et al. (2006) n–3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 5–17.
8. Global Organisation for EPA and DHA (2014) Global recommendations for EPA and DHA intake. Revised 16th April 2014.
9. Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17, 1–12.
10. Eslick GD, Howe PR, Smith C et al. (2009) Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 136, 4–16.
11. Balk EM, Lichtenstein AH, Chung M et al. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189, 19–30.
12. Di Angelantonio E, Sarwar N, Perry P et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000.
13. Miller PE, Van Elswyk M & Alexander DD (2014) Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 27, 885–896.
14. Ndanuko RN, Tapsell LC, Charlton KE et al. (2016) Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 7, 76–89.
15. Mozaffarian D, Geelen A, Brouwer IA et al. (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.
16. Pearson TA, Mensah GA, Alexander RW et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511.
17. Xin W, Wei W & Li X (2012) Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 12, 77.
18. EFSA (2010) EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL-cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL-cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo-oxidative (UV-induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines (ID 520, 2914), and “immunomodulating agent” (4690) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 8, 1796 [32 pp.]. https://doi.org/10.2903/j.efsa.2010.1796. Available online: www.efsa.europa.eu/efsajournal.htm ©. 2010.
19. Kris-Etherton PM & Fleming JA (2015) Emerging nutrition science on fatty acids and cardiovascular disease: nutritionists’ perspectives. Adv Nutr 6, 326S–337S.
20. Andreassen AK, Hartmann A, Offstad J et al. (1997) Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 29, 1324–1331.
21. Bach R, Schmidt U, Jung F et al. (1989) Effects of fish oil capsules in two dosages on blood pressure, platelet functions, haemorheological and clinical chemistry parameters in apparently healthy subjects. Ann Nutr Metab 33, 359–367.
22. Bairati I, Roy L & Meyer F (1992) Effects of a fish oil supplement on blood pressure and serum lipids in patients treated for coronary artery disease. Can J Cardiol 8, 41–46.
23. Berrettini M, Parise P, Ricotta S et al. (1996) Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Thromb Haemost 75, 395–400.
24. Berstad P, Seljeflot I, Veierod MB et al. (2003) Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) 105, 13–20.
25. Bloomer RJ, Larson DE, Fisher-Wellman KH et al. (2009) Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis 8, 36.
26. Boberg M, Pollare T, Siegbahn A et al. (1992) Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 22, 645–650.
27. Bonaa KH, Bjerve KS & Nordoy A (1992) Docosahexaenoic and eicosapentaenoic acids in plasma phospholipids are divergently associated with high density lipoprotein in humans. Arterioscler Thromb 12, 675–681.
28. Borthwick L (1998) The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Investig 15, 397–404.
29. Bosch J, Gerstein HC, Dagenais GR et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367, 309–318.
30. Buckley JD, Burgess S, Murphy KJ et al. (2009) DHA-rich fish oil lowers heart rate during submaximal exercise in elite Australian Rules footballers. J Sci Med Sport 12, 503–507.
31. Buckley R, Shewring B, Turner R et al. (2004) Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 92, 477–483.
32. Calabresi L, Villa B, Canavesi M et al. (2004) An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53, 153–158.
33. Calabresi L, Donati D, Pazzucconi F et al. (2000) Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 148, 387–396.
34. Carney RM, Freedland KE, Stein PK et al. (2010) Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosom Med 72, 748–754.
35. Carter JR, Schwartz CE, Yang H et al. (2012) Fish oil and neurovascular control in humans. Am J Physiol Heart Circ Physiol 303, H450–H456.
36. Caslake MJ, Miles EA, Kofler BM et al. (2008) Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 88, 618–629.
37. Castro IA, Monteiro VC, Barroso LP et al. (2007) Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia. Nutrition 23, 127–137.
38. Cazzola R, Russo-Volpe S, Miles EA et al. (2007) Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193, 159–167.
39. Chan DC, Nguyen MN, Watts GF et al. (2010) Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr 91, 900–906.
40. Charman A, Muriithi EW, Milne E et al. (2005) Fish oil before cardiac surgery: neutrophil activation is unaffected but myocardial damage is moderated. Prostaglandins Leukot Essent Fatty Acids 72, 257–265.
41. Christensen JH, Christensen MS, Dyerberg J et al. (1999) Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 70, 331–337.
42. Ciubotaru I, Lee YS & Wander RC (2003) Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 14, 513–521.
43. Conquer JA & Holub BJ (1996) Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 126, 3032–3039.
44. Damsgaard CT, Frokiaer H, Andersen AD et al. (2008) Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J Nutr 138, 1061–1066.
45. Davidson MH, Stein EA, Bays HE et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29, 1354–1367.
46. Dawczynski C, Martin L, Wagner A et al. (2010) n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study. Clin Nutr 29, 592–599.
47. Durrington PN, Bhatnagar D, Mackness MI et al. (2001) An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85, 544–548.
48. Dyerberg J, Eskesen DC, Andersen PW et al. (2004) Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 58, 1062–1070.
49. Egert S, Kannenberg F, Somoza V et al. (2009) Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 139, 861–868.
50. Eschen O, Christensen JH, De Caterina R et al. (2004) Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 14, 180–185.
51. Eschen, O, Christensen, JH, LA Rovere, MT et al. (2010) Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) 56, 45–51.
52. Fakhrzadeh H, Ghaderpanahi M, Sharifi F et al. (2010) The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial. Int J Vitam Nutr Res 80, 107–116.
53. Finnegan YE, Minihane AM, Leigh-Firbank EC et al. (2003) Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am J Clin Nutr 77, 783–795.
54. Finnegan YE, Howarth D, Minihane AM et al. (2003) Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. J Nutr 133, 2210–2213.
55. Flaten H, Hostmark AT, Kierulf P et al. (1990) Fish-oil concentrate: effects on variables related to cardiovascular disease. Am J Clin Nutr 52, 300–306.
56. Fuchs J, Beigel Y, Green P et al. (1992) Big platelets in hyperlipidemic patients. J Clin Pharmacol 32, 639–642.
57. Fujioka S, Hamazaki K, Itomura M et al. (2006) The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects – a randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol (Tokyo) 52, 261–265.
58. Gajos G, Rostoff P, Undas A et al. (2010) Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 55, 1671–1678.
59. Gajos G, Zalewski J, Rostoff P et al. (2011) Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 31, 1696–1702.
60. Gammelmark A, Madsen T, Varming K et al. (2012) Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects. Nutr Res 32, 15–23.
61. Geelen A, Brouwer IA, Schouten EG et al. (2005) Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr 81, 416–420.
62. Geppert J, Kraft V, Demmelmair H et al. (2006) Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br J Nutr 95, 779–786.
63. Goode GK, Garcia S & Heagerty AM (1997) Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 96, 2802–2807.
64. Goyens PL & Mensink RP (2006) Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects. Eur J Clin Nutr 60, 978–984.
65. Green P, Fuchs J, Schoenfeld N et al. (1990) Effects of fish-oil ingestion on cardiovascular risk factors in hyperlipidemic subjects in Israel: a randomized, double-blind crossover study. Am J Clin Nutr 52, 1118–1124.
66. Grimsgaard S, Bonaa KH, Hansen JB et al. (1997) Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 66, 649–659.
67. Grimsgaard S, Bonaa KH, Hansen JB et al. (1998) Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 68, 52–59.
68. Gunnarsdottir I, Tomasson H, Kiely M et al. (2008) Inclusion of fish or fish oil in weight-loss diets for young adults: effects on blood lipids. Int J Obes (Lond) 32, 1105–1112.
69. Hamazaki K, Itomura M, Huan M et al. (2003) n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans. Lipids 38, 353–358.
70. Harris WS & Muzio F (1993) Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates. Am J Clin Nutr 58, 68–74.
71. Harrison RA, Sagara M, Rajpura A et al. (2004) Can foods with added soya-protein or fish-oil reduce risk factors for coronary disease? A factorial randomised controlled trial. Nutr Metab Cardiovasc Dis 14, 344–350.
72. Hill AM, Buckley JD, Murphy KJ et al. (2007) Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 85, 1267–1274.
73. Hjerkinn EM, Abdelnoor M, Breivik L et al. (2006) Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 13, 325–333.
74. Holm T, Berge RK, Andreassen AK et al. (2001) Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients. Transplantation 72, 706–711.
75. Howe PR, Lungershausen YK, Cobiac L et al. (1994) Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors. J Hum Hypertens 8, 43–49.
76. Hong H, Xu ZM, Pang BS et al. (2004) Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. Chin Med Sci J 19, 145–149.
77. Hughes GS, Ringer TV, Watts KC et al. (1990) Fish oil produces an atherogenic lipid profile in hypertensive men. Atherosclerosis 84, 229–237.
78. Iacoviello L, Amore C, De Curtis A et al. (1992) Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids. Arterioscler Thromb 12, 1191–1197.
79. Jellema A, Plat J & Mensink RP (2004) Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 34, 766–773.
80. Jensen T, Stender S, Goldstein K et al. (1989) Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med 321, 1572–1577.
81. Johansen O, Brekke M, Seljeflot I et al. (1999) N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol 33, 1619–1626.
82. Kabir M, Skurnik G, Naour N et al. (2007) Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 86, 1670–1679.
83. Kaul N, Kreml R, Austria JA et al. (2008) A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. J Am Coll Nutr 27, 51–58.
84. Kelley DS, Siegel D, Fedor DM et al. (2009) DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 139, 495–501.
85. Kelley DS, Siegel D, Vemuri M et al. (2007) Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 86, 324–333.
86. Khandelwal S, Demonty I, Jeemon P et al. (2009) Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults. Br J Nutr 102, 722–732.
87. Knapp HR & FitzGerald GA (1989) The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 320, 1037–1043.
88. Krebs JD, Browning LM, McLean NK et al. (2006) Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond) 30, 1535–1544.
89. Layne KS, Goh YK, Jumpsen JA et al. (1996) Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels. J Nutr 126, 2130–2140.
90. Leaf A, Jorgensen MB, Jacobs AK et al. (1994) Do fish oils prevent restenosis after coronary angioplasty? Circulation 90, 2248–2257.
91. Levinson PD, Iosiphidis AH, Saritelli AL et al. (1990) Effects of n-3 fatty acids in essential hypertension. Am J Hypertens 3, 754–760.
92. Lofgren RP, Wilt TJ, Nichol KL et al. (1993) The effect of fish oil supplements on blood pressure. Am J Public Health 83, 267–269.
93. Luo J, Rizkalla SW, Vidal H et al. (1998) Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 21, 717–724.
94. Mackness MI, Bhatnagar D, Durrington PN et al. (1994) Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr 48, 859–865.
95. Maki KC, Lawless AL, Kelley KM et al. (2011) Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic beta-cell response in subjects with primary hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids 85, 143–148.
96. Maki KC, McKenney JM, Reeves MS et al. (2008) Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102, 429–433.
97. Maki KC, Van Elswyk ME, McCarthy D et al. (2005) Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 24, 189–199.
98. Margolin G, Huster G, Glueck CJ et al. (1991) Blood pressure lowering in elderly subjects: a double-blind crossover study of omega-3 and omega-6 fatty acids. Am J Clin Nutr 53, 562–572.
99. McGrath LT, Brennan GM, Donnelly JP et al. (1996) Effect of dietary fish oil supplementation on peroxidation of serum lipids in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 121, 275–283.
100. McVeigh GE, Brennan GM, Cohn JN et al. (1994) Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 14, 1425–1429.
101. Mehta JL, Lopez LM, Lawson D et al. (1988) Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on indices of platelet and neutrophil function and exercise performance. Am J Med 84, 45–52.
102. Meland E, Fugelli P, Laerum E et al. (1989) Effect of fish oil on blood pressure and blood lipids in men with mild to moderate hypertension. Scand J Prim Health Care 7, 131–135.
103. Mills DE, Mah M, Ward RP et al. (1990) Alteration of baroreflex control of forearm vascular resistance by dietary fatty acids. Am J Physiol 259, R1164–R1171.
104. Milte CM, Coates AM, Buckley JD et al. (2008) Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. Br J Nutr 99, 1083–1088.
105. Minihane AM, Khan S, Leigh-Firbank EC et al. (2000) ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20, 1990–1997.
106. Miyajima T, Tsujino T, Saito K et al. (2001) Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res 24, 537–542.
107. Moertl D, Hammer A, Steiner S et al. (2011) Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 161, 915.e911–e919.
108. Morgan WA, Raskin P & Rosenstock J (1995) A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. Diabetes Care 18, 83–86.
109. Morgan DR, Dixon LJ, Hanratty CG et al. (2006) Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol 97, 547–551.
110. Mori TA, Woodman RJ, Burke V et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772–781.
111. Mori TA, Burke V, Puddey IB et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 1085–1094.
112. Mori TA, Bao DQ, Burke V et al. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253–260.
113. Mori TA, Vandongen R, Mahanian F et al. (1992) Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. Metabolism 41, 1059–1067.
114. Mostad IL, Bjerve KS, Lydersen S et al. (2008) Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 62, 419–429.
115. Murphy KJ, Meyer BJ, Mori TA et al. (2007) Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. Br J Nutr 97, 749–757.
116. Nau KL, Katch VL & Tsui AC (1991) Omega-3 polyunsaturated fatty acid supplementation alters selective plasma lipid values in adults with heart disease. J Cardiopul Rehabil 11, 386–391.
117. Neff LM, Culiner J, Cunningham-Rundles S et al. (2011) Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr 141, 207–213.
118. Neil HA, Ceglarek U, Thiery J et al. (2010) Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 213, 512–517.
119. Nestel P, Shige H, Pomeroy S et al. (2002) The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 76, 326–330.
120. Nilsen DW, Albrektsen G, Landmark K et al. (2001) Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 74, 50–56.
121. Ninio DM, Hill AM, Howe PR et al. (2008) Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults. Br J Nutr 100, 1097–1103.
122. Nordoy A, Bonaa KH, Sandset PM et al. (2000) Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 20, 259–265.
123. Nordoy A, Hansen JB, Brox J et al. (2001) Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 11, 7–16.
124. Nordoy A, Bonaa KH, Nilsen H et al. (1998) Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 243, 163–170.
125. O'Keefe JH Jr, Abuissa H, Sastre A et al. (2006) Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 97, 1127–1130.
126. Olano-Martin E, Anil E, Caslake MJ et al. (2010) Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 209, 104–110.
127. Park Y & Harris WS (2009) Dose-response of n-3 polyunsaturated fatty acids on lipid profile and tolerability in mildly hypertriglyceridemic subjects. J Med Food 12, 803–808.
128. Park Y, Jones PG & Harris WS (2004) Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids. Am J Clin Nutr 80, 45–50.
129. Park Y & Harris WS (2003) Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 44, 455–463.
130. Passfall J, Philipp T, Woermann F et al. (1993) Different effects of eicosapentaenoic acid and olive oil on blood pressure, intracellular free platelet calcium, and plasma lipids in patients with essential hypertension. Clin Investig 71, 628–633.
131. Paulo MC, Andrade AM, Andrade ML et al. (2008) Influence of n-3 polyunsaturated fatty acids on soluble cellular adhesion molecules as biomarkers of cardiovascular risk in young healthy subjects. Nutr Metab Cardiovasc Dis 18, 664–670.
132. Pedersen H, Petersen M, Major-Pedersen A et al. (2003) Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. Eur J Clin Nutr 57, 713–720.
133. Petersen M, Pedersen H, Major-Pedersen A et al. (2002) Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 25, 1704–1708.
134. Plat J, Jellema A, Ramakers J et al. (2007) Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. J Nutr 137, 2635–2640.
135. Pooya S, Jalali MD, Jazayery AD et al. (2010) The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis 20, 326–331.
136. Poppitt SD, Howe CA, Lithander FE et al. (2009) Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 40, 3485–3492.
137. Prisco D, Paniccia R, Bandinelli B et al. (1998) Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 91, 105–112.
138. Prisco D, Paniccia R, Filippini M et al. (1994) No changes in PAI-1 levels after four-month n-3 PUFA ethyl ester supplementation in healthy subjects. Thromb Res 76, 237–244.
139. Radack K, Deck C & Huster G (1991) The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects. A randomized controlled trial. Arch Intern Med 151, 1173–1180.
140. Radack K, Deck C & Huster G (1989) Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 111, 757–758.
141. Radack KL, Deck CC & Huster GA (1990) n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. Am J Clin Nutr 51, 599–605.
142. Rahbar AR, Nabipour I & Amiri Z (2007) Effects of omega-3 fatty acids on serum lipids and high sensitivity C reactive protein in cigarette smokers. J Biol Sci 7, 1368–1374.
143. Reis GJ, Silverman DI, Boucher TM et al. (1990) Effects of two types of fish oil supplements on serum lipids and plasma phospholipid fatty acids in coronary artery disease. Am J Cardiol 66, 1171–1175.
144. Rivellese AA, Maffettone A, Iovine C et al. (1996) Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19, 1207–1213.
145. Rizza S, Tesauro M, Cardillo C et al. (2009) Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis 206, 569–574.
146. Rogers S, James KS, Butland BK et al. (1987) Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, haemostatic and rheological variables. A double blind randomised controlled trial in healthy volunteers. Atherosclerosis 63, 137–143.
147. Sacks FM, Stone PH, Gibson CM et al. (1995) Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 25, 1492–1498.
148. Salachas A, Papadopoulos C, Sakadamis G et al. (1994) Effects of a low-dose fish oil concentrate on angina, exercise tolerance time, serum triglycerides, and platelet function. Angiology 45, 1023–1031.
149. Sanders TA, Hall WL, Maniou Z et al. (2011) Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr 94, 973–980.
150. Sanders TA, Sullivan DR, Reeve J et al. (1985) Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis 5, 459–465.
151. Sanders TA & Mistry M (1984) Controlled trials of fish oil supplements on plasma lipid concentrations. Br J Clin Pract Suppl 31, 78–84.
152. Schuchardt JP, Neubronner J, Kressel G et al. (2011) Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids 85, 381–386.
153. Shidfar F, Keshavarz A, Jalali M et al. (2004) Effects of purified omega-3 fatty acids on serum lipoproteins and malondialdehyde in postmenopausal fat women receiving hormone replacement therapy. Int J Endocrinol Metab 2, 87–94.
154. Shidfar F, Keshavarz A, Hosseyni S et al. (2008) Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients. East Mediterr Health J 14, 305–313.
155. Shidfar F, Keshavarz A, Jallali M et al. (2003) Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients. Int J Vitam Nutr Res 73, 163–170.
156. Silva JM, Souza I, Silva R et al. (1996) The triglyceride lowering effect of fish oils is affected by fish consumption. Int J Cardiol 57, 75–80.
157. Simons LA, Hickie JB & Balasubramaniam S (1985) On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis 54, 75–88.
158. Singer P & Wirth M (2004) Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids 71, 153–159.
159. Sirtori CR, Paoletti R, Mancini M et al. (1997) N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr 65, 1874–1881.
160. Sjoberg NJ, Milte CM, Buckley JD et al. (2010) Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation. Br J Nutr 103, 243–248.
161. Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243–252.
162. Solomon SA, Cartwright I, Pockley G et al. (1990) A placebo-controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina pectoris. Curr Med Res Opin 12, 1–11.
163. Stark KD & Holub BJ (2004) Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 79, 765–773.
164. Stark KD, Park EJ, Maines VA et al. (2000) Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial. Am J Clin Nutr 72, 389–394.
165. Stirban A, Nandrean S, Gotting C et al. (2010) Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91, 808–813.
166. Suzukawa M, Abbey M, Howe PR et al. (1995) Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 36, 473–484.
167. Swahn E, von Schenck H & Olsson AG (1998) Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig 15, 473–482.
168. Szabo de Edelenyi F, Vergnaud AC, Ahluwalia N et al. (2012) Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD. Br J Nutr 107, 921–927.
169. Tato F, Keller C & Wolfram G (1993) Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia. Clin Investig 71, 314–318.
170. Theobald HE, Goodall AH, Sattar N et al. (2007) Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 137, 973–978.
171. Theobald HE, Chowienczyk PJ, Whittall R et al. (2004) LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 79, 558–563.
172. Thies F, Miles EA, Nebe-von-Caron G et al. (2001) Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 36, 1183–1193.
173. Tinker LF, Parks EJ, Behr SR et al. (1999) (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. J Nutr 129, 1126–1134.
174. Toft I, Bonaa KH, Ingebretsen OC et al. (1997) Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol 17, 814–819.
175. Toft I, Bonaa KH, Ingebretsen OC et al. (1995) Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 123, 911–918.
176. Vacek JL, Harris WS & Haffey K (1989) Short-term effects of omega-3 fatty acids on exercise stress test parameters, angina and lipoproteins. Biomed Pharmacother 43, 375–379.
177. Valdini AF, Glenn MA, Greenblatt L et al. (1990) Efficacy of fish oil supplementation for treatment of moderate elevation of serum cholesterol. J Fam Pract 30, 55–59.
178. Vericel E, Calzada C, Chapuy P et al. (1999) The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis 147, 187–192.
179. Ventura HO, Milani RV, Lavie CJ et al. (1993) Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation. Circulation 88, II281–II285.
180. Wang S, Ma AQ, Song SW et al. (2008) Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. Eur J Clin Nutr 62, 1426–1431.
181. Watanabe N, Watanabe Y, Kumagai M et al. (2009) Administration of dietary fish oil capsules in healthy middle-aged Japanese men with a high level of fish consumption. Int J Food Sci Nutr 60(Suppl 5), 136–142.
182. Wilt TJ, Lofgren RP, Nichol KL et al. (1989) Fish oil supplementation does not lower plasma cholesterol in men with hypercholesterolemia. Results of a randomized, placebo-controlled crossover study. Ann Intern Med 111, 900–905.
183. Wing LM, Nestel PJ, Chalmers JP et al. (1990) Lack of effect of fish oil supplementation on blood pressure in treated hypertensives. J Hypertens 8, 339–343.
184. Wong CY, Yiu KH, Li SW et al. (2010) Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med 27, 54–60.
185. Woodman RJ, Mori TA, Burke V et al. (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166, 85–93.
186. Woodman RJ, Mori TA, Burke V et al. (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76, 1007–1015.
187. Wu WH, Lu SC, Wang TF et al. (2006) Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr 60, 386–392.
188. Yusof HM, Miles EA & Calder P (2008) Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78, 219–228.
189. Zhao YT, Shao L, Teng LL et al. (2009) Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 37, 1831–1841.
190. Zucker ML, Bilyeu DS, Helmkamp GM et al. (1988) Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis 73, 13–22.